Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Other Non Operating Income (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Other Non Operating Income for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 58.57% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 23.33% decrease, with the full-year FY2025 number at $8.8 million, down 49.57% from a year prior.
  • Other Non Operating Income was $2.2 million for Q4 2025 at Caribou Biosciences, up from $2.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $5.3 million in Q4 2024 to a low of $16000.0 in Q1 2021.
  • A 5-year average of $2.5 million and a median of $2.3 million in 2022 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 72.29% in 2021, then skyrocketed 6273.91% in 2022.
  • Caribou Biosciences' Other Non Operating Income stood at $23000.0 in 2021, then surged by 10034.78% to $2.3 million in 2022, then surged by 106.61% to $4.8 million in 2023, then grew by 10.26% to $5.3 million in 2024, then tumbled by 58.57% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Other Non Operating Income are $2.2 million (Q4 2025), $2.2 million (Q2 2025), and $5.3 million (Q4 2024).